US-listed Chinese firms wracked by infighting amid delisting threat
Minority shareholders risk losing out as Sinovac and Hollysys refuse to accept buyout offers. But, seemingly unfazed by the prospect of delisting, will the firms pursue value creation elsewhere?
November 21, 2022